KidneyCure Ltd. is developing proprietary cell therapies aiming to prevent progression of Chronic Kidney Disease. KidneyCure’s approach is based on it's proprietary 3D renal cell cluster technology, whereby special renal stem cells are extracted from the patient's kidney and grown ex-vivo to provide 3D renal cell complexes, that are subsequently injected back into the patient's kidney. This technology is expected to significantly delay CKD progression, and the resulting need for dialysis and transplantation in advanced CKD patients, thereby giving millions of patients an opportunity to live longer, higher quality lives.
Employees: 11-50
Total raised: $47M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Aurum Vent... | aurum.co.i... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.08.2015 | Series D | $27M | - |
| 25.05.2011 | Series C | $20M | - |
Mentions in press and media 3
| Date | Title | Description |
| 05.08.2015 | LifeBond Closes $27M Series D Equity Funding | LifeBond, a Caesarea Industrial Park, Israel-based developer of bio-surgical medical devices for tissue repair, closed a $27M Series D equity funding. Participants in the round include Pitango Venture Capital, Adams Street Partners, Sino Bi... |
| 05.08.2015 | Daily funding roundup - August 5, 2015 | Fastly raised $75M; LifeBond closed $27M; Ptengine closed $9M Ptengine, which helps businesses see what visitors are doing, and allows them to turn those actions into actionable intelligence, closed a $9 million Pre-A series funding round. ... |
| 25.05.2011 | LifeBond Closes $20M Series C Financing Round | LifeBond, a Caesarea, Israel-biosurgery device company that is developing a line of biosurgical products for prevention of surgical leakage and bleeding, has closed a $20m Series C financing round. The round wad led by Giza Venture Capital ... |